🇺🇸 FDA
Patent

US 9006283

Methods of modifying amyloid β oligomers using non-peptidic compounds

granted A61KA61K31/381A61K31/41

Quick answer

US patent 9006283 (Methods of modifying amyloid β oligomers using non-peptidic compounds) held by Acumen Pharmaceuticals, Inc. expires Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Acumen Pharmaceuticals, Inc.
Grant date
Tue Apr 14 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/381, A61K31/41, A61K31/415, A61K9/0019